The human COX-2 ELISA kit is a solid-phase immunoassay specially designed to quantitatively measure human COX-2 in serum, plasma, cell lysates, or tissue homogenates. It is based on the Sandwich-ELISA mechanism. COX-2 in the sample is bound to the capture antibody immobilized on the 96-well strip plate and then sandwiched with the biotinylated COX-2 antibody. After the addition of HRP-avidin and TMB substrate, the solution in the wells turns blue. The color reaction is stopped by adding the stop solution into the wells, and the color changes from blue to yellow. The color intensity is positively proportional to the COX-2 bound in the initial step. The COX-2 concentration can be calculated according to the standard curve. This kit is tested with high sensitivity, strong specificity, good linearity, high precision and recovery, as well as lot-to-lot consistency.
COX-2 (PTGS2) catalyzes the conversion of arachidonic acid to prostaglandins and is an inducible type of cyclo-oxygenase. It is primarily responsible for inflammation, pain, and fever. COX-2 overexpression has been found in a variety of malignancies, including colorectal, breast, pancreatic, and lung cancers, and has been linked to a bad prognosis. In response to synaptic excitement, neuronal COX-2 is activated, releasing PGE2, the most common COX-2 metabolite in the brain, which increases glutamate release and neuronal firing in a retrograde manner. COX-2 is also involved in the synthesis of new endocannabinoids from 2-arachidonoyl-glycerol in order to control their activities at presynaptic terminals.